Andreas Wicki Sells 70,498 Shares of Pacira Pharmaceuticals Inc (PCRX) Stock
Pacira Pharmaceuticals Inc (NASDAQ:PCRX) Director Andreas Wicki sold 70,498 shares of the firm’s stock in a transaction dated Friday, November 16th. The stock was sold at an average price of $47.34, for a total value of $3,337,375.32. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Andreas Wicki also recently made the following trade(s):
- On Monday, November 12th, Andreas Wicki sold 5,478 shares of Pacira Pharmaceuticals stock. The stock was sold at an average price of $49.83, for a total value of $272,968.74.
- On Friday, November 9th, Andreas Wicki sold 58,245 shares of Pacira Pharmaceuticals stock. The stock was sold at an average price of $51.11, for a total value of $2,976,901.95.
Shares of PCRX stock opened at $45.91 on Wednesday. The company has a market cap of $1.92 billion, a price-to-earnings ratio of -79.16, a price-to-earnings-growth ratio of 80.00 and a beta of 1.68. The company has a current ratio of 8.66, a quick ratio of 7.83 and a debt-to-equity ratio of 0.95. Pacira Pharmaceuticals Inc has a 12-month low of $26.95 and a 12-month high of $55.00.
Several research firms recently commented on PCRX. ValuEngine lowered Pacira Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday. Barclays raised their target price on Pacira Pharmaceuticals from $40.00 to $50.00 and gave the stock a “buy” rating in a report on Monday, August 6th. Piper Jaffray Companies set a $48.00 target price on Pacira Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, August 2nd. Canaccord Genuity reiterated a “hold” rating and set a $34.00 price target on shares of Pacira Pharmaceuticals in a research report on Monday, July 30th. Finally, Royal Bank of Canada set a $55.00 price target on Pacira Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, September 19th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and nine have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $53.76.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in PCRX. US Bancorp DE lifted its position in shares of Pacira Pharmaceuticals by 40.7% in the second quarter. US Bancorp DE now owns 6,038 shares of the company’s stock valued at $194,000 after acquiring an additional 1,746 shares in the last quarter. Cubist Systematic Strategies LLC lifted its position in shares of Pacira Pharmaceuticals by 1,925.8% in the second quarter. Cubist Systematic Strategies LLC now owns 6,665 shares of the company’s stock valued at $214,000 after acquiring an additional 6,336 shares in the last quarter. Xact Kapitalforvaltning AB purchased a new position in shares of Pacira Pharmaceuticals in the second quarter valued at approximately $219,000. Bouchey Financial Group Ltd purchased a new position in shares of Pacira Pharmaceuticals in the third quarter valued at approximately $221,000. Finally, Boston Private Wealth LLC purchased a new position in shares of Pacira Pharmaceuticals in the third quarter valued at approximately $246,000.
About Pacira Pharmaceuticals
Pacira Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.
Featured Story: Balanced Fund
Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.